Insight

Aggressive Lymphoma after CD19 CAR T-Cell Therapy suggested by Vivek Subbiah

Vivek Subbiah/LinkedIn

Oct 11, 2024, 15:13

Aggressive Lymphoma after CD19 CAR T-Cell Therapy suggested by Vivek Subbiah

Vivek Subbiah shared a post on X:

“Aggressive Lymphoma after CD19 CAR T-Cell Therapy clonal hematopoiesis had contributed to lymphomagenesis.”

Aggressive Lymphoma after CD19 CAR T-Cell Therapy

Authors: Guido Kobbe, et al.

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

cancer cancer awareness cancer care CAR T-CELL CAR T-cell therapy fight against cancer Global fight against cancer lymphoma lymphomagenesis OncoDaily Oncology Vivek Subbiah

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma